长春胺缓释胶囊治疗血管性认知功能障碍:与尼莫地平的对照

Comparison between Changchun’an sustained-release capsules and Nimodipine for the treatment of vascular cognitive impairment

目的:观察长春胺缓释胶囊治疗血管性认知障碍的疗效,并与尼莫地平片进行比较。方法:选取血管性认知功能障碍患者120例,按患者意愿随机分为治疗组与对照组,每组60例。治疗组口服长春胺缓释胶囊,30mg/次,2次/d,对照组口服尼莫地平片,30mg/次,3次/d,疗程均为6个月。观察临床疗效、简易精神状态量表和日常生活能力量表得分情况。结果:长春胺缓释胶囊治疗组总有效率60.0%,尼莫地平对照组总有效率53.3%,两组比较差异有显著意义(P<0.05);两组治疗前、后简易精神状态量表、日常生活能力量表得分情况比较,均有明显的改善(P<0.01),两组治疗后比较差异有显著意义(P<0.05);药物不良反应治疗组明显少于对照组。结论:长春胺缓释胶囊治疗血管性认知功能障碍疗效肯定,不良反应少。

OBJECTIVE： To compare the therapeutic effect of Changchun’an sustained-release capsules and Nimodipine tablets on the treatment of vascular cognitive impairment. METHODS： A total of 120 patients with vascular cognitive impairment were randomly divided into treatment group and control group, with 60 patients for each group. Patients in the treatment group were treated with Changchun’an sustained-release capsules, 30 mg for each administration, twice a day; the other patients in the control group were treated with Nimodipine tablets, 30 mg for each administration, 3 times a day. The treatment course was 6 months for both groups. The scores of clinical efficiency, Mini-Mental State Examination （MMSE）, and Activity of Daily Living Scale （ADL） were analyzed. RESULTS： The total effective rates of Changchun’an sustained-release capsules and Nimodipine tablets were 60.0% and 53.3%, respectively, and there was significant difference in the total effective rates between treatment and control groups （P 〈 0.05）. The scores of MMSE and ADL in both groups were improved obviously after treatment compared with before treatment （P 〈 0.01）, and there was a significant difference between the two groups after treatment （P 〈 0.05）. The side effects of Changchun’an sustained-release capsules were obviously posterior to those of Nimodipine tablets. CONCLUSION： Changchun’an sustained-release capsules are effective in treating vascular cognitive impairment with few side effects.